UBI Pharma Balance Sheet Health
Financial Health criteria checks 4/6
UBI Pharma has a total shareholder equity of NT$1.2B and total debt of NT$92.5M, which brings its debt-to-equity ratio to 7.9%. Its total assets and total liabilities are NT$1.8B and NT$666.8M respectively. UBI Pharma's EBIT is NT$5.5M making its interest coverage ratio 0.9. It has cash and short-term investments of NT$340.3M.
Key information
7.9%
Debt to equity ratio
NT$92.46m
Debt
Interest coverage ratio | 0.9x |
Cash | NT$340.30m |
Equity | NT$1.17b |
Total liabilities | NT$666.84m |
Total assets | NT$1.84b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6562's short term assets (NT$680.4M) exceed its short term liabilities (NT$218.7M).
Long Term Liabilities: 6562's short term assets (NT$680.4M) exceed its long term liabilities (NT$448.1M).
Debt to Equity History and Analysis
Debt Level: 6562 has more cash than its total debt.
Reducing Debt: 6562's debt to equity ratio has reduced from 85.7% to 7.9% over the past 5 years.
Debt Coverage: 6562's debt is not well covered by operating cash flow (7.5%).
Interest Coverage: 6562's interest payments on its debt are not well covered by EBIT (0.9x coverage).